Open-label study to assess efficacy and safety of a single dose (i.v.) of NMA78 in PS or ET patients and HV

Open-label study to assess efficacy and safety of a single dose (i.v.) of NMA78 in patients with Parkinson's Syndrome (PS) or Essential Tremor (ET) and healthy volunteers (HV)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221472

Enrollment

Registered

2011-06-01

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PS:Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy(PSP), ET

Interventions

investigational material(s) Generic name etc : NMA78 INN of investigational material : ioflupane(123I) Therapeutic category code : 729 Other diagnostic agents (except extracorporeal diagnostic medicin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: [HV] - Healthy Japanese people. [PD] - Japanese patients clinically- diagnosed with PD. [MSA] - Japanese patients clinically- diagnosed with MSA. [PSP] - Japanese patients clinically- diagnosed with PSP. [ET] - Japanese patients clinically- diagnosed with ET.

Exclusion criteria

Exclusion criteria: -Patients clinically-diagnosed with dementia. -Patients using following drugs: cocaine hydrochloride, mazindol, methylphenidate hydrochloride, sertraline hydrochloride. -Patients with hepatic, renal or hematopoietic dysfunction. -People with allergic reaction to alcohol or iodine. -Women who are pregnant, lactating or possibly pregnant.

Design outcomes

Primary

Measure	Time frame
Efficacy: diagnostic accuracy by reading committee Safety: subjective/objective symptoms, vital signs, electrocardiogram, clinical tests	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026